Clinical Trial Update: Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab plus tremelimumab in progressive, refractory advanced thyroid carcinoma (papillary and follicular subtypes) has been termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Thyroid Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2026-03-11